At a Glance
- Vaxart's newest independent directors sent a letter to shareholders emphasizing value.
- The letter details commitments to strategic review, capital allocation, and governance.
- Directors aim to enhance shareholder returns and advance oral vaccine development.
Vaxart, Inc. (Nasdaq: VXRT) recently announced that its two newest independent directors, James Breitmeyer, M.D., Ph.D., and Kevin Finney, have issued a letter to shareholders. Sent ahead of the company's 2026 Annual Meeting, the communication outlines their dedication to improving shareholder value and strengthening corporate governance. The directors' message highlights their active involvement in Vaxart's strategic and operational discussions since joining the board.
Independent Directors' Vision for Vaxart
In their letter, Dr. Breitmeyer and Mr. Finney articulated their focus on Vaxart’s strategic direction, operational efficiency, and capital allocation. Their overarching objective is to position Vaxart effectively to deliver on its potential for groundbreaking oral vaccines. They aim to maximize returns for all shareholders through these efforts.
The directors expressed strong confidence in Vaxart's proprietary oral vaccine platform, recognizing its capacity to address significant global medical needs. They stressed the importance of transparent communication with shareholders and pledged to cultivate a culture of accountability within both the Board and management. This approach underscores their commitment to responsible oversight and corporate integrity.
Key commitments detailed in the letter include a thorough strategic review of existing clinical programs and the research pipeline. This review will prioritize initiatives with the highest potential for success and market impact. Furthermore, they plan to implement disciplined capital allocation practices to prolong the company’s financial runway and support promising programs, ensuring long-term stability.
Recommendations for corporate governance enhancements are also a priority, including possible adjustments to board composition and committee structures. These changes would align with best practices in corporate governance, aiming to improve oversight and decision-making. The directors also committed to continuous dialogue with shareholders to integrate their feedback into strategic decisions, reflecting a dedication to business resilience in shifting global markets.
"Since joining the Board, we have been actively engaged in discussions regarding Vaxart’s strategic direction, operational efficiency, and capital allocation. Our shared goal is to ensure Vaxart is best positioned to deliver on its promise of developing groundbreaking oral vaccines and to maximize returns for all shareholders."
— James Breitmeyer, M.D., Ph.D. and Kevin Finney, Independent Directors, Vaxart, Inc.
Advancing Oral Vaccine Development and Shareholder Confidence
Mr. Finney emphasized that his experience in biotech leadership and financial management provides a meaningful contribution to Vaxart’s future. He believes that collaborative efforts with current management and the Board can accelerate Vaxart’s progress toward commercialization and sustainable growth. This collaborative spirit is central to their strategy.
Dr. Breitmeyer highlighted the compelling science underpinning Vaxart’s oral vaccine platform. His focus will be on translating this scientific promise into tangible value for both patients and shareholders. He aims to ensure that every investment contributes directly to the company's ultimate objectives.
The letter also addressed the upcoming Annual Meeting, urging shareholders to support the current Board’s nominees. This support is deemed essential for maintaining continuity and stability as the company undergoes strategic refinement. The directors reiterated their unwavering dedication to acting in the best interests of all shareholders and driving long-term value creation for Vaxart, Inc..
Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines through its proprietary platform. These vaccines, administered as tablets rather than injections, offer potential benefits in accessibility, distribution, and patient adherence. The company's pipeline includes vaccine candidates for COVID-19, norovirus, and influenza, representing key areas for future growth and impact.